Please assess the completion status of the following clinical trial:

Trial Title: Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients between 18 years and 80 years.~2. Patients having moderate to severe IBD according to European Crohn's and colitis organization (ECCO) guidelines.~3. IBD patients receiving either IFX or ADA.~Exclusion Criteria:~1. Patients missed one-year follow-up or with missed data.~2. Patients having mild IBD according to ECCO guidelines.~3. Patients having any of the Contraindications to the biological Therapy e.g.: latent TB, viral or fungal or bacterial infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Infliximab. (Type: ACTIVE_COMPARATOR): group 1 (n=20): patients will receive IFX,
- Adalimumab. (Type: ACTIVE_COMPARATOR): group 2 (n=20): patients will receive ADA

Based on this trial design, predict the completion outcome and termination type (if applicable).